

AN 1998:112682 CAPLUS
 DN 128:221671
 TI Improved cancer treatment with temozolomide
 IN Radenburg, Pascal; Dougan, Margaret H.
 PA Schering Corp., USA
 SO Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 IC ICM A61K031-415
 ICS C07D487-04
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI JP 10045589 A2 19980217 JP 1996-232394 19960902
 CA 2184545 AA 19980201 CA 1996-2184545 19960830
 PRAI US 1996-690707 19960731
 AB A method for treating cancer in a patient in need of such treatment comprises administering temozolomide in an amt. sufficient to achieve a clin. response, wherein the temozolomide is administered more than once per day. Preferred aspect of the invention is administration of temozolomide twice, three times or four times per day. A capsule contained temozolomide 5, lactose 132.8, Na starch glycolate 7.5, colloidal silica 0.2, tartaric acid 1.5, and stearic acid 3 mg.
 ST temozolomide capsule cancer treatment
 IT Oral drug delivery systems
 (bolus; improved cancer treatment with temozolomide)
 IT Brain tumor inhibitors
 Breast tumor inhibitors
 Capsules (drug delivery systems)
 Carcinoma inhibitors
 Colon tumor inhibitors
 Glioblastoma inhibitors
 Glioma inhibitors
 Leukemia inhibitors
 Lung tumor inhibitors
 Lymphoma inhibitors
 Melanoma inhibitors
 Sarcoma inhibitors
 (improved cancer treatment with temozolomide)
 IT Testicular tumors
 (inhibitors; improved cancer treatment with temozolomide)
 IT Skin tumors
 T cell lymphoma
 (mycosis fungoides, inhibitors; improved cancer treatment with temozolomide)
 IT Antitumor agents
 Colorectal tumors
 (rectal tumor inhibitors; improved cancer treatment with temozolomide)
 IT Antitumor agents
 (testicular; improved cancer treatment with temozolomide)
 IT 85622-93-1, Temozolomide
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (improved cancer treatment with temozolomide)